Satellos Bioscience Inc. announced the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders, including Duchenne muscular dystrophy (DMD or Duchenne). The members of the Clinical Advisory Board (CAB) are as follows: Jordan Dubow, M.D., Chair of the CAB and Chief Medical Advisor, Satellos, has extensive experience in the biopharmaceutical industry, leading all aspects of clinical and regulatory development in Chief Medical Officer (CMO) capacities for both public and private companies, playing pivotal roles on 16 new drug applications (NDAs), including in DMD. Ronald Cohn, M.D., Ph.D., President and CEO, Hospital for Sick Children, is an outstanding clinician scientist devoted to discovering new diagnostic and treatment options for pediatric disease and an accomplished scientist dedicated to muscular dystrophies.

Research in his laboratory focuses on utilizing genome editing technologies like CRISPR for the development of therapeutic approaches for neurogenetic disorders. Richard Finkel, M.D., Director, Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, is an experienced translational researcher and international leader in organizing key clinical trials for neuromuscular diseases, including DMD and spinal muscular atrophy, for which he played a vital role in developing the first successful therapy.

Nicholas Johnson, M.D., MSCI, FAAN, Director of the Center for Inherited Myology Research, George Bliley Research Chair, and Professor and Vice Chair of Research in Neurology, conducts therapeutic trials in inherited nerve and muscle disorders and also dedicates significant time to laboratory research as part of a team at VCU Health working to advance the treatment of genetic muscle disorders, with a special emphasis on muscular dystrophies. Hanns Lochmüller, M.D., Ph.D., Senior Scientist, Children?s Hospital of Eastern Ontario Research Institute, is a neurologist and clinical academic focused on clinical research and care of patients with rare genetic neuromuscular disorders. His research includes molecular therapies of neuromuscular disorders and molecular pathogenesis of muscle and neuromuscular junction disorders.

Francesco Muntoni, M.D., Director, Dubowitz Neuromuscular Centre, Great Ormond Street UCL Institute of Child Health, is focused on advancing novel therapeutics in translational and clinical research for pediatric neuromuscular disorders, especially Duchenne muscular dystrophy. His efforts in the last 20 years led to two FDA-approved therapies for DMD (eteplirsen and golodirsen). Perry Shieh, M.D., Ph.D., FAAN, Professor of Neurology, UCLA David Geffen School of Medicine.

Dr. Shieh?s principal clinical interests include Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and myotonic dystrophy. He has served as an investigator in numerous clinical trials for neuromuscular conditions.